Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636861 | 1.00 | CDK1 (0.49) | CDK1YTHDC1GRM5DYRK1AADORA2A | |
| SCHEMBL17813482 | 0.78 | GRM5 (0.41) | CDK1YTHDC1GRM5DYRK1AADORA2A | |
| SCHEMBL24682199 | 0.77 | PI4KA (0.39) | CDK1YTHDC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL743863 | 0.77 | KDM4E (0.36) | CDK1YTHDC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29141665 | 0.77 | ADORA2A (0.41) | CDK1ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL31085096 | 0.76 | GRM5 (0.40) | CDK1YTHDC1GRM5DYRK1AADORA2A | |
| SCHEMBL28235448 | 0.76 | GRM5 (0.40) | CDK1YTHDC1GRM5DYRK1AADORA2A | |
| SCHEMBL2983374 | 0.76 | DYRK1A (0.46) | CDK1YTHDC1GRM5DYRK1AADORA2A | |
| SCHEMBL1496411 | 0.76 | CDK2 (0.46) | CDK1DYRK1AADORA2AADORA1ALDH1A1 | |
| SCHEMBL5839419 | 0.76 | FGFR1 (0.40) | CDK1YTHDC1ADORA2AADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1894234-A | Dipeptidyl peptidase inhibitors | SYRRX INC (JP) | 2007-01-10 | — | — | CN | claimed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4626881-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123968-A1 | RNA TARGETING COMPOUNDS AND USES THEREOF | RANAR THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024118858-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4305031-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| CN-102711766-A | N-9-substituted purine compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| CN-102459272-A | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | GENENTECH INC | 2012-05-16 | — | — | CN | disclosed |
| CN-102361859-A | Heteroaryl compounds useful as Raf kinase inhibitors | BIOGEN IDEC INC | 2012-02-22 | — | — | CN | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2379513-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-26 | — | — | EP | disclosed |
| CN-102105474-A | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| CN-101675050-A | Purines as cysteine protease inhibitors | GLAXO GROUP LTD | 2010-03-17 | — | — | CN | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| CN-1894234-A | Dipeptidyl peptidase inhibitors | SYRRX INC (JP) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | CDK1 530/4885YTHDC1 2430/4885GRM5 4424/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CDK1 252/4885YTHDC1 4510/4885GRM5 4437/4885 |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | TYK2, IRAK3, JAK3 | CDK1 572/4885YTHDC1 1537/4885GRM5 2395/4885 |
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | CDK1 1595/4885YTHDC1 3844/4885GRM5 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.